Artemether-lumefantrine and Dihydroartemisinin-Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar.

The emergence of artemisinin-resistant Plasmodium falciparum in the Greater Mekong Subregion threatens both the efficacy of artemisinin-based combination therapy (ACT), the first-line treatment for malaria, and prospects for malaria elimination. Monitoring of ACT efficacy is essential for ensuring timely updates to elimination policies and treatment recommendations. In 2014-2015, we assessed the therapeutic efficacies of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated P. falciparum at three study sites in Rakhine, Shan, and Kachin states in Myanmar. Patients presenting with uncomplicated P. falciparum malaria were enrolled, treated, and followed up for 28 days for AL or 42 days for DP. Both AL and DP demonstrated good therapeutic efficacy at all three study sites. The 28-day cure rate for AL was > 96% across all study sites, and the 42-day cure rate for DP was 100%. Parasitemia on day 3 was detected in 0%, 3.3%, and 3.6% of participants treated with AL at the Rakhine, Shan, and Kachin sites, respectively. No participants treated with DP were parasitemic on day 3. No evidence of P. falciparum k13 mutations was found at the Rakhine study site. High prevalence of k13 mutations associated with artemisinin resistance was observed at the Kachin and Shan state study sites. These results confirm that ACT efficacy has been resilient in TES sentinel sites in Myanmar, despite the presence at some sites in Myanmar of k13 mutations associated with resistance. Studies are ongoing to assess whether this resilience persists.

[1]  Richard J Maude,et al.  Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study , 2019, The Lancet. Infectious diseases.

[2]  Dongmei Zhang,et al.  Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in Plasmodium falciparum isolates , 2018, Malaria Journal.

[3]  Mehul Dhorda,et al.  Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme , 2018, The Lancet.

[4]  K. Thimasarn,et al.  Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013) , 2017, Malaria Journal.

[5]  P. Ringwald,et al.  Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies , 2017, Malaria Journal.

[6]  L. Cui,et al.  Significant Divergence in Sensitivity to Antimalarial Drugs between Neighboring Plasmodium falciparum Populations along the Eastern Border of Myanmar , 2016, Antimicrobial Agents and Chemotherapy.

[7]  D. Kwiatkowski,et al.  Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration , 2016, Malaria Journal.

[8]  N. Anstey,et al.  Malaria incidence in Myanmar 2005–2014: steady but fragile progress towards elimination , 2016, Malaria Journal.

[9]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[10]  Zbynek Bozdech,et al.  Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  E. Ashley,et al.  Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study , 2016, Malaria Journal.

[12]  M. Fay,et al.  Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. , 2016, The Lancet. Infectious diseases.

[13]  K. Chotivanich,et al.  K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar , 2016, Malaria Journal.

[14]  R. Fairhurst.  High Antimalarial Efficacy of Dihydroartemisinin–Piperaquine on the China–Myanmar Border: The Calm before the Storm , 2015, The American journal of tropical medicine and hygiene.

[15]  Guofa Zhou,et al.  Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border. , 2015, The American journal of tropical medicine and hygiene.

[16]  L. Cui,et al.  Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene , 2015, Antimicrobial Agents and Chemotherapy.

[17]  Shui-sen Zhou,et al.  A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. , 2015, The Journal of infectious diseases.

[18]  L. Cui,et al.  Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007–2012 , 2015, Malaria Journal.

[19]  John C. Tan,et al.  Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. , 2015, The Journal of infectious diseases.

[20]  F. Huang,et al.  In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013 , 2015, Malaria Journal.

[21]  A. Rosanas-Urgell,et al.  Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam , 2014, Antimicrobial Agents and Chemotherapy.

[22]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[23]  F. Nosten,et al.  Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study , 2013, PLoS medicine.

[24]  K. Na-Bangchang,et al.  Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border , 2010, Malaria Journal.

[25]  Anand P. Patil,et al.  Estimating the Global Clinical Burden of Plasmodium falciparum Malaria in 2007 , 2010, PLoS medicine.

[26]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[27]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[28]  P. Ringwald,et al.  Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia , 2006, Tropical medicine & international health : TM & IH.

[29]  L. H. Taylor,et al.  Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[31]  K. Tun.  Artemisinin resistant falciparum malaria in Myanmar , 2015 .

[32]  C. Wongsrichanalai,et al.  Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010. , 2013, The Southeast Asian journal of tropical medicine and public health.

[33]  Organización Mundial de la Salud.  Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations , 2008 .